{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-008195","form_type":"8-K","ticker":"BLGO","cik":"0000880242","company_name":"BIOLARGO, INC.","filed_at":"2022-04-04T23:59:59+00:00","discovered_at":"2026-05-14T18:04:04.082755+00:00","generated_at":"2026-06-26T10:02:17.509469+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"BioLargo 2021 revenue $2.53M (+4%), net loss down 29% to $6.9M, debt cut to $0.68M","bullets":["Revenue of $2,531,000 for FY2021, a 4% increase from 2020; Q4 revenue $784,000 (+10% QoQ).","Net loss reduced 29% to $6.9M, including $1.9M non-cash option expense and $342K impairment.","Total debt slashed from $2.9M to $681K; total liabilities down from $5.2M to $2.1M.","AEC PFAS treatment passed tests with municipality and federal agency; Garratt-Callahan MLD prototype completed.","Ikigai partnership for pet odor product exceeds initial projections; Clyra's Bioclynse secures two hospital customers."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-008195","json":"https://secwatch.observer/filing/0001437749-22-008195.json","markdown":"https://secwatch.observer/filing/0001437749-22-008195.md","text":"https://secwatch.observer/filing/0001437749-22-008195.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/880242/000143774922008195/0001437749-22-008195-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/880242/000143774922008195/blgo20220404_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T10:02:17.509469+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}